Characteristics of triple-negative breast cancer

Epidermal Growth Factor Receptor in Triple-Negative and Basal-Like Breast Cancer

(2010) Monika L. Burness et al.   CANCER JOURNAL

443 PARP is expressed in all subtypes of early breast cancer and is a predictive factor for response to neoadjuvant chemotherapy

(2010) G. von Minckwitz et al.   EJC SUPPLEMENTS

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Basal Cytokeratin and Epidermal Growth Factor Receptor Expression Are Not Predictive of BRCA1 Mutation Status in Women With Triple-negative Breast Cancers

(2009) Laura C. Collins et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer

(2009) M. D. Green et al.   ANNALS OF ONCOLOGY

Trastuzumab treatment in patients with breast cancer and metastatic CNS disease

(2009) T. Pienkowski et al.   ANNALS OF ONCOLOGY

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

(2009) B. Corkery et al.   ANNALS OF ONCOLOGY

Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers

(2009) Sharon Nofech-Mozes et al.   BREAST CANCER RESEARCH AND TREATMENT

Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53-Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin

(2009) T. Hay et al.   CANCER RESEARCH

A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies

(2009) H. A. Burris et al.   CLINICAL CANCER RESEARCH

Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes

(2009) E. A. Rakha et al.   CLINICAL CANCER RESEARCH

Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial

(2009) Judith Hugh et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes

(2009) X. Hu et al.   MOLECULAR CANCER RESEARCH

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of established breast cancer in post-menopausal women: Role of aromatase inhibitors

(2009) S. Samphao et al.   SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND

Platinum-based chemotherapy in triple-negative breast cancer

(2008) B. Sirohi et al.   ANNALS OF ONCOLOGY

Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women

(2008) HAWA NALWOGA et al.   APMIS

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer

(2008) Jiyoung Rhee et al.   BMC CANCER

The prognostic importance of triple negative breast carcinoma

(2008) Hakan Mersin et al.   BREAST

Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity

(2008) Giuseppe Viale et al.   BREAST CANCER RESEARCH AND TREATMENT

Impact of Triple Negative Phenotype on Breast Cancer Prognosis

(2008) Henry G. Kaplan et al.   Breast Journal

Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer

(2008) S Kyle et al.   BRITISH JOURNAL OF RADIOLOGY

Therapeutic Strategies for Triple-Negative Breast Cancer

(2008) Antoinette R. Tan et al.   CANCER JOURNAL

“New” molecular taxonomy in breast cancer

(2008) Marta Hergueta-Redondo et al.   Clinical & Translational Oncology

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

(2008) M. C.U. Cheang et al.   CLINICAL CANCER RESEARCH

DNA copy number alterations and expression of relevant genes in triple-negative breast cancer

(2008) Wonshik Han et al.   GENES CHROMOSOMES & CANCER

EGFR family: Structure physiology signalling and therapeutic targets†

(2008) Antony W. Burgess   GROWTH FACTORS

How basal are triple-negative breast cancers?

(2008) François Bertucci et al.   INTERNATIONAL JOURNAL OF CANCER

Prognostic Value of Triple-Negative Phenotype at the Time of Locally Recurrent, Conservatively Treated Breast Cancer

(2008) Rahul R. Parikh et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY

Refinement of breast cancer classification by molecular characterization of histological special types

(2008) B Weigelt et al.   JOURNAL OF PATHOLOGY

Nuclear Factor One Transcription Factors in CNS Development

(2008) Sharon Mason et al.   MOLECULAR NEUROBIOLOGY

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Is triple negative a prognostic factor in breast cancer?

(2008) Reiki Nishimura et al.   Breast Cancer

Evaluation of Morphologic Features to Identify “Basal-like Phenotype” on Core Needle Biopsies of Breast

(2008) Mamatha Chivukula et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Clinicopathologic and Prognostic Characteristics of Triple-Negative Breast Cancer

(2008) Xing-song Tian et al.   Oncology Research and Treatment